ASX:LDX Lumos Diagnostics (LDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lumos Diagnostics Stock (ASX:LDX) 30 days 90 days 365 days Advanced Chart Get Lumos Diagnostics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationA$14.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia. Read More Receive LDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LDX Stock News HeadlinesLumos Diagnostics Earnings Call: Mixed Sentiments and Strategic GrowthSeptember 4, 2025 | msn.comLumos Diagnostics to Announce FY25 Financial Results and Host Investor BriefingAugust 26, 2025 | msn.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.September 13 at 2:00 AM | Banyan Hill Publishing (Ad)StockTake: Lumos submits CLIA waiver application to FDA for FebriDxAugust 19, 2025 | msn.comLumos Diagnostics Seeks CLIA Waiver for FebriDx® to Expand U.S. MarketAugust 18, 2025 | msn.comASX Market Close: Index hits new all-time high | August 14, 2025August 14, 2025 | msn.comLumos Diagnostics Partners with PRO-spectus to Expand FebriDx® Access in the USAugust 14, 2025 | msn.comCompanies Like Lumos Diagnostics Holdings (ASX:LDX) Can Afford To Invest In GrowthJuly 16, 2025 | finance.yahoo.comSee More Headlines LDX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Lumos Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Diagnostics investors own include T2 Biosystems (TTOO), GT Biopharma (GTBP) and Aditxt (ADTX). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryBanking Current SymbolASX:LDX CIKN/A Weblumosdiagnostics.com Phone61 3 9692 7222FaxN/AEmployees217,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$8.59 million Net Margins-77.19% Pretax MarginN/A Return on Equity-105.19% Return on Assets-18.32% Debt Debt-to-Equity Ratio113.38 Current Ratio0.76 Quick Ratio0.77 Sales & Book Value Annual SalesA$11.13 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares562,990,000Free FloatN/AMarket CapA$14.13 million OptionableNot Optionable Beta0.78 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (ASX:LDX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Diagnostics Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LDX Stock Alerts